 Leap Therapeutics Inc NASDAQ: LPTX stock increased over 30 premarket as the investors are responding positively ahead of the Companys presentation of new data from the first-line cohort of the DisTinGuish study. The Phase 2a trial is evaluating Leaps anti-Dickkopf-1 DKK1 antibody, DKN-01, in combination with BeiGene Ltds NASDAQ: BGNE tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer GGEJ. 